Key Drivers
- Strong Margins
- Solid Cash Flow
- Manageable Leverage
AIAI Summary
MDT is shifting from a defensive medtech name to a self-help/innovation re-rating story driven by cardiac ablation, Hugo robotics and portfolio actions, but the stock likely won't re-rate until these launches prove they can translate into durable margin expansion despite tariff, mix and integration pressure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Solid Cash Flow
- •Manageable Leverage
Medtronic remains a high-quality cash generator with strong margins, solid liquidity, manageable leverage, and dividend support, but its valuation is rich and balance-sheet intangibles warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support bounce
- •Upper-70s cap
MDT remains technically weak, with a last-month downtrend of lower highs and lower lows, and only a modest bounce off $74.54 while resistance in the upper-$70s still caps recovery.
ക
Brief rebound above $76 after holding support at $74.54
Sentiment & News
Key News Insights:
- •Margin recovery
- •Share weakness
- •Diabetes spin-off
Medtronic is advancing acquisitions, partnerships, and restructuring to improve margins and growth, but the stock remains under pressure amid muted expectations and mixed valuation signals.
The news points to steady strategic progress, but the stock may stay range-bound until investors see clearer evidence of growth and operating improvement
Similar Companies in Healthcare
Other companies in the same sector with AI ratings